After six months of mepolizumab, the patient had normalization of his peripheral eosinophilia, C-ANCA, MPO, and inflammatory markers, and was able to taper off prednisone without recurrent orbital inflammation. Here, PRTN3 is linked to Increased total eosinophil count.